CME/CE Podcast: Residual Risk in Chronic Kidney Disease: Impacts and Options

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/residual-risk-in-chronic-kidney-disease-8865

Featuring faculty Robert D. Toto, MD, moderated by Gregg Sherman, MD.

Summary
Chronic kidney disease (CKD) is estimated to affect 20%–40% of patients with diabetes mellitus. All-cause mortality in patients with diabetic kidney disease (DKD) is 30-fold higher than in individuals who have diabetes without CKD, and many of these deaths are due to cardiovascular disease (CVD).  Traditional steroidal MR antagonists (MRAs) are beneficial but are associated with hyperkalemia. 

In this first of two podcast episodes, Dr. Robert Toto and Dr. Gregg Sherman discuss the impact of MR overactivation on cardiovascular risk and CKD progression in patients with diabetes, as well as the mechanism of action and recent data regarding newer non-steroidal MRA and emerging treatment options for CKD of T2D. 
This podcast was recorded and is being used with permission of the presenters.

Learning Objectives

• Recognize the impact of mineralocorticoid receptor (MR) overactivation on cardiovascular risk and chronic kidney disease (CKD) progression in patients with diabetes
• Summarize the mechanism of action, efficacy, and safety of non-steroidal MR antagonists (MRAs) and other emerging treatment options for CKD of T2D

This activity is accredited for CME/CE Credit.
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.  The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).

Summary of Individual Disclosures
Robert Toto has disclosed the following financial relationships:

• Consultant: Amgen (Anemia in CKD), AstraZeneca (CKD), Akebia (Anemia in CKD), Bayer (CKD), Boehringer Ingelheim (CKD), Medscape (CKD anemia and hyperkalemia), Novartis (CKD), Novo Nordisk (Diabetic Kidney Disease), Otsuka (Anemia in CKD), Vifor (CKD), CinCor (CKD)
• Advisor – Unicycive (hyperphosphatemia in CKD)

Angela Golden has disclosed the following financial relationships:

• Consultant: SetPoint (Obesity), WW (Obesity)
• Advisor: Currax (Obesity), Genesis (Obesity), Lilly (Obesity), Novo Nordisk (Obesity), (Obesity), Acela (Hypothyroidism)
• Speaker: Currax, Novo Nordisk (Obesity)
• Receipt of Royalty: Amazon (fiction books), Springer (obesity book)

Faculty, planners, guest patient(s) (if applicable), and moderators for this educational activity not listed in the Summary of Individual Disclosures above have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Disclosure of Commercial Support
This activity has been supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.